（文章来源：证券日报） 证券日报网讯宏力达11月14日在互动平台回答投资者提问时表示，公司主要股东持股情况参见公司定期 报告及相关公告。 ...

Core Viewpoint - The company has integrated edge computing technology into its smart pole switch products, enhancing real-time analysis and fault diagnosis capabilities [2] Group 1 - The smart pole switch products utilize edge computing to analyze voltage and current information in real-time [2] - The technology allows for on-site fault diagnosis and determination of fault types, leading to improved response speed and decision-making efficiency [2] - The implementation results in rapid and accurate fault assessment and autonomous decision-making [2]

（文章来源：证券日报） 证券日报网讯宏力达11月14日在互动平台回答投资者提问时表示，公司在不影响生产经营活动正常运行 的情况下统筹调配资金，提高资本运作的效率，努力为股东创造长期价值。 ...

Core Insights - The company, Honglida, has developed a core technology product, the intelligent pole-mounted switch, which integrates traditional electrical switches, IoT sensing devices, edge computing, and industrial control equipment to enhance fault diagnosis, location, and isolation efficiency [2] - The product has achieved remote human-machine interaction and has received high recognition from users [2] - Continuous innovation and R&D are based on long-term operational field characteristic data, optimizing product design, improving fault diagnosis data algorithms, and developing new fault diagnosis models to enhance accuracy and speed of fault handling [2]

一、说明会类型 会议问题征集：投资者可于 2025 年 11 月 20 日下午 17:00 前访问网址 https://eseb.cn/1tc4B4ia4yA 或扫描下方小程序码点击"互动交流"，进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进 行回答。 关于举办 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688330 证券简称：宏力达 公告编号：2025-043 上海宏力达信息技术股份有限公司 二、说明会召开的时间、地点和方式 会议召开时间：2025 年 11 月 21 日（星期五）15:30-16:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络文字互动 三、参加人员 出席公司本次业绩说明会的有：董事长章辉先生，董事、总经理冷春田先生， 独立董事文东华先生，财务总监张占先生，董事会秘书宫文静女士（如有特殊情 况，参会人员将可能调整）。 四、投资者参加方式 投 资 者 可 于 ： ...

每经AI快讯，有投资者在投资者互动平台提问：请董秘及时介绍公司参股的太空电源公司馥昶空间本 轮融资的估值情况，并介绍本轮投后宏力达持股比例是多少？ （记者 王瀚黎） 宏力达（688330.SH）11月14日在投资者互动平台表示，公司通过专项基金参投苏州馥昶空间技术有限 公司，间接持股比例较低，且未参与馥昶空间的日常经营管理，馥昶空间的具体情况请您关注其公开信 息。 ...

Group 1 - The core viewpoint of the article highlights the growth in the electrical machinery and equipment manufacturing industry in China, with a notable increase in export value [1] - In September 2025, the export value of the electrical machinery and equipment manufacturing industry reached 150.53 billion yuan, representing a year-on-year growth of 7% [1] - From January to September 2025, the cumulative export value was 1,333.73 billion yuan, with a year-on-year increase of 6.4% [1] Group 2 - The article lists several publicly listed companies in the electrical machinery sector, including XJ Electric, Dongfang Electronics, and Jinzhiketech, among others [1] - The data presented is sourced from the National Bureau of Statistics and compiled by Zhiyan Consulting, indicating a robust market outlook for the industry [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, providing comprehensive industry research reports and consulting services [1]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]

Core Viewpoint - Honglida (688330.SH) reported its Q3 2025 results, highlighting a significant presence of institutional investors holding 40.35% of its total shares, although this represents a slight decrease from the previous quarter [1] Group 1: Institutional Investors - As of October 30, 2025, five institutional investors disclosed their holdings in Honglida A-shares, totaling 56.4851 million shares [1] - The total shareholding by institutional investors decreased by 0.52 percentage points compared to the previous quarter [1] - The institutional investors include Shanghai Hongyuan Investment Group Co., Ltd., Shanghai Yuehai Investment Center (Limited Partnership), Shanghai Hongyuan Contract Energy Management Center (Limited Partnership), Beijing Yueyunshan Enterprise Management Co., Ltd., and Shanghai Pinhua Investment Consulting Co., Ltd. [1] Group 2: Public Funds - In this reporting period, 48 public funds were disclosed, which were not reported in the previous quarter [1] - Notable public funds include Dachen Jingheng Mixed A, Guotai Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive ETF, Shanghai Composite Index ETF, Huatai-PineBridge Shanghai Composite Index A, and Dachen Zhuoxiang One-Year Holding Mixed A [1]

Group 1 - The company announced the convening of the fourth board meeting on October 30, 2025, to review the proposal regarding the reversal of asset impairment provisions for the third quarter of 2025 [2] - The amount reversed for asset impairment provisions in the third quarter of 2025 is 25.6518 million yuan [2]